

STATUS OF APPLICATIONS FOR RETAIL PRICE

| Sl. No. | Acknowledgement Number | IPDMS Reference Number | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Date of receipt of application | STATUS |
|---------|------------------------|------------------------|--|--|-----------|--|--------------------------------|--------------------------------------|
| 1 | RPON2022110522 | | Ibuprofen Injection | Each ml contains: Ibuprofen IP 100mg | Injection | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Cipla Ltd. | 03-11-2022 | To be placed 52nd MDC |
| 2 | RPON2023020045 | 123010004 | Sitagliptin Phosphate and Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 50mg Metformin Hydrochloride IP 500mg | Tablet | M/s MSN Laboratories Pvt. Ltd. / M/s Sanofi India Limited | 01-02-2023 | To be placed 115th Authority Meeting |
| 3 | RPON2023020047 | 123010005 | Sitagliptin Phosphate and Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg | Tablet | M/s MSN Laboratories Pvt. Ltd. / M/s Sanofi India Limited | 01-02-2023 | To be placed 115th Authority Meeting |
| 4 | RPON2023030101 | | Ambroxol Hydrochloride, Salbutamol Sulphate, Guaiphenesin & Methol Liquid | Each 5ml contains: Ambroxol Hydrochloride IP 15mg Salbutamol Sulphate IP eq. to Salbutamol 1mg Guaiphenesin IP 50mg Methol IP 1mg | Syrup | M/s Naxpar Pharma Pvt. Ltd. / M/s Geno Pharmaceuticals Pvt. Ltd. | 07-03-2023 | To be placed 52nd MDC |
| 5 | RPON2023040147 | | Diclofenac Dimethylamine, Methyl Salicylate & Menthol Topical Gel | contains: Diclofenac Dimethylamine IP 2.32% (eq. to Diclofenac Sodium 2% w/w) Methyl Salicylate IP 10.00% w/w Menthol IP 5.0% w/w | Gel | M/s Pontika Aeratech Limited / M/s Intas Pharmaceuticals Pvt. Ltd. | 10-04-2023 | To be placed 115th Authority Meeting |
| 6 | RPON2023040164 | | Pneumococcal polysaccharide conjugate Vaccine (Adsorbed) IP (14 Valent) | Singal dose vial of 0.5ml Each dose of 0.5ml contains: Pneumococcal polysaccharide serotype 1 3.0 µg Pneumococcal polysaccharide serotype 3, 4, 5, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F 2.2 µg Pneumococcal polysaccharide serotype 6B 4.4 µg Adsorbed onto Aluminium Phosphate, as Al*** ≤ 0.75 Mg Polysaccharides conjugated to 20-50µg of CRM ₁₉₇ | Injection | M/s Biological E. Limited | 21-04-2023 | Clarification sought From NHM |
| 7 | RPON2023040167 | 123040012 | Nimesulide & Paracetamol tablet | Each uncoated bilayered tablet contains: Nimesulide BP 100mg Paracetamol IP 325mg | Tablet | M/s Lucent Biotech Limited / M/s Torrent Pharmaceuticals Ltd. | 26-04-2023 | Clarification sought From DCGI |
| 8 | RPON2023040168 | 123040011 | Ceftazidime and Avibactam powder for concentrate for solution for infusion | Each vial contains: Ceftazidime Pentahydrate IP eq. to Ceftazidime 2.0gm Avibactam Sodium eq. to Avibactam 0.5gm | Injection | M/s Protech Telelinks / M/s Samarth Life Sciences Pvt. Ltd. | 26-04-2023 | Working sheet uploaded |
| 9 | RPON2023040170 | | Paroxetine (PR) & Clonazepam Capsules | Each Hard gelatine capsule contains: Paroxetine Hydrochloride Hemihydrate IP eq. to Paroxetine 12.5mg (As enteric coated paroxetine prolonged release tablets IP) Clonazepam IP 0.5mg (as uncoated clonazepam tablets IP) | Capsule | M/s Windlas Biotech Limited / M/s Eris Lifesciences Limited | 28-04-2023 | To be placed 115th Authority Meeting |
| 10 | RPON2023040172 | 123040013 | Pantoprazole Sodium (CR) & Levosulpiride (SR) Capsules | Each Hard gelatine capsule contains: Pantoprazole Sodium Sesquihydrate IP eq. to Pantoprazole 40mg (As Enteric Coated Pellets) Levosulpiride 75mg (As Sustained Release Pellets) | Capsule | M/s Lucent Biotech Limited / M/s Torrent Pharmaceuticals Ltd. | 29-04-2023 | Working sheet uploaded |
| 11 | RPON2023050177 | | Telmisartan and Chlorthalidone Tablet | Each film coated tablet contains: Telmisartan IP 40mg Chlorthalidone IP 6.25mg | Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s La Renon Healthcare Pvt. Ltd. | 02-05-2023 | Working sheet uploaded |

| Sl. No. | Acknowledgement Number | IPDMS Reference Number | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Date of receipt of application | STATUS |
|---------|------------------------|------------------------|---|---|----------|--|--------------------------------|--------------------------------------|
| 12 | RPON2023050181 | | Pantoprazole Dual-release Gastro-resistant Tablet | Each Dual-release Gastro-resistant tablet contains: Pantoprazole Sodium IP eq. to Pantoprazole 80mg | Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Cadila Pharmaceuticals Ltd. | 03-05-2023 | To be placed 115th Authority Meeting |
| 13 | RPON2023050184 | 123050005 | Dapagliflozin, Sitagliptin and Metformin Hydrochloride (ER) Tablets | Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100mg Metformin Hydrochloride IP 500mg (As Extended Release form) | Tablet | M/s Synkem Pharmaceuticals Ltd. / M/s Unison Pharmaceuticals Pvt. Ltd. | 04-05-2023 | Under Examination |
| 14 | RPON2023050185 | 123050006 | Dapagliflozin, Sitagliptin and Metformin Hydrochloride (ER) Tablets | Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100mg Metformin Hydrochloride IP 1000mg (As Extended Release form) | Tablet | M/s Synkem Pharmaceuticals Ltd. / M/s Unison Pharmaceuticals Pvt. Ltd. | 04-05-2023 | Under Examination |
| 15 | RPON2023050191 | | Telmisartan and Cilnidipine Tablet | Each film coated tablet contains: Telmisartan IP 40mg Cilnidipine IP 10mg | Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Indchemie Health Specialities Pvt. Ltd. | 08-05-2023 | To be placed 115th Authority Meeting |
| 16 | RPON2023050193 | | Itraconazole Capsule (Supra-Bioavailable formulation) | Each Capsule contains: Itraconazole IP 65mg | Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Indchemie Health Specialities Pvt. Ltd. | 08-05-2023 | To be placed 115th Authority Meeting |
| 17 | RPON2023050194 | | Levetiracetam + Sodium Chloride Infusion | Each 100ml contains: Levetiracetam IP 500mg Sodium Chloride IP 820mg | Infusion | M/s Akum Drugs & Pharmaceuticals Ltd. / M/s Mankind Pharma Ltd. | 08-05-2023 | To be placed 115th Authority Meeting |
| 18 | RPON2023050195 | 123050007 | Linagliptin and Metformin Hydrochloride Tablets | Each film coated tablet contains: Linagliptin IP 2.5mg Metformin Hydrochloride IP 500mg | Tablet | M/s Exemed Pharmaceuticals / M/s Abbott Healthcare Pvt. Ltd. | 04-05-2023 | Working sheet uploaded |
| 19 | RPON2023050196 | 123050008 | Linagliptin and Metformin Hydrochloride Tablets | Each film coated tablet contains: Linagliptin IP 2.5mg Metformin Hydrochloride IP 1000mg | Tablet | M/s Exemed Pharmaceuticals / M/s Abbott Healthcare Pvt. Ltd. | 04-05-2023 | Working sheet uploaded |
| 20 | RPON2023050197 | | Tacrolimus Capsule | Each hard gelatin capsule contains: Tacrolimus IP eq. to Anhydrous Tacrolimus 0.25mg | Capsule | M/s Rivpra Formulation s Pvt. Ltd. / M/s RPG Life Sciences Ltd. | 12-05-2023 | To be placed 115th Authority Meeting |
| 21 | RPON2023050198 | 123050010 | Dapagliflozin, Sitagliptin and Metformin Hydrochloride (ER) Tablets | Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100mg Metformin Hydrochloride IP 500mg (As Extended Release form) | Tablet | M/s Synkem Pharmaceuticals Ltd. / M/s Primus Remedies Pvt Ltd | 12-05-2023 | Under Examination |
| 22 | RPON2023050199 | 123050011 | Levocetirizine, Montelukast & (SR) Ambroxol Hydrochloride Tablets | Each uncoated bilayered tablet contains: Levocetirizine Hydrochloride IP 5mg Montelukast Sodium IP eq. to Montelukast 10mg Ambroxol Hydrochloride IP 75mg (As sustained Release) | Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Cipla Ltd. | 12-05-2023 | To be placed 115th Authority Meeting |

| Sl. No. | Acknowledgement Number | IPDMS Reference Number | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Date of receipt of application | STATUS |
|---------|------------------------|------------------------|--|--|-----------|--|--------------------------------|--------------------------------------|
| 23 | RPON2023050200 | 123050012 | Dapagliflozin, Sitagliptin and Metformin Hydrochloride (ER) Tablets | Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100mg Metformin Hydrochloride IP 1000mg (As Extended Release form) | Tablet | M/s Synkem Pharmaceuticals Ltd. / M/s Primus Remedies Pvt Ltd | 12-05-2023 | Under Examination |
| 24 | RPON2023050202 | | Telmisartan and Bisoprolol Fumarate Tablets | Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 2.5mg | Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Zuventus Healthcare Limited | 17-05-2023 | To be placed 115th Authority Meeting |
| 25 | RPON2023050203 | | Telmisartan and Bisoprolol Fumarate Tablets | Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 5mg | Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Zuventus Healthcare Limited | 17-05-2023 | To be placed 115th Authority Meeting |
| 26 | RPON2023050206 | 123050015 | Sodium Chloride water for Injection 500ml Pack | Each 100ml contains: Lactic Acid IP 0.24ml (eq. to Sodium Lactate 0.32gm) Sodium Chloride IP 0.60gm Potassium Chloride IP 0.04gm Calcium Chloride IP 0.027gm Water for Injection | Injection | M/s Puniska Healthcare Pvt. Ltd. | 18-05-2023 | Clarification sought From DCGI |
| 27 | RPON2023050208 | 123050022 | Chlorthalidone, Amlodipine & Telmisartan Tablets | Each film coated tablet contains: Chlorthalidone IP 6.25mg Amlodipine Besylate IP eq. to Amlodipine 5mg Telmisartan IP 40mg | Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Cipla Ltd. | 20-05-2023 | To be placed 115th Authority Meeting |
| 28 | RPON2023050209 | 123050023 | Ceftazidime and Avibactam powder for concentrate for solution for infusion | Each vial contains: Ceftazidime (As Ceftazidime pentahydrate) IP 2gram Avibactam Sodium eq. to Avibactam 0.5gm | Infusion | M/s BDR Pharmaceuticals International Pvt. Ltd. / M/s Natco Pharma Limited | 20-05-2023 | Under Examination |
| 29 | RPON2023050210 | 123050024 | Chlorthalidone, Amlodipine & Telmisartan Tablets | Each film coated tablet contains: Chlorthalidone IP 12.5mg Amlodipine Besylate IP eq. to Amlodipine 5mg Telmisartan IP 40mg | Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Cipla Ltd. | 20-05-2023 | To be placed 115th Authority Meeting |
| 30 | RPON2023050211 | 123050025 | Chlorthalidone, Amlodipine & Telmisartan Tablets | Each film coated tablet contains: Chlorthalidone IP 6.25mg Amlodipine Besylate IP eq. to Amlodipine 5mg Telmisartan IP 80mg | Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Cipla Ltd. | 20-05-2023 | To be placed 115th Authority Meeting |
| 31 | RPON2023050212 | 123050026 | Chlorthalidone, Amlodipine & Telmisartan Tablets | Each film coated tablet contains: Chlorthalidone IP 12.5mg Amlodipine Besylate IP eq. to Amlodipine 5mg Telmisartan IP 80mg | Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Cipla Ltd. | 20-05-2023 | To be placed 115th Authority Meeting |
| 32 | RPON2023050213 | 123050027 | Faropenem Sodium & Potassium Clavulanate Tablets | Each film coated tablet contains: Faropenem Sodium eq. to Faropenem 200mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 125mg | Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Cipla Ltd. | 20-05-2023 | To be placed 115th Authority Meeting |

| Sl. No. | Acknowledgement Number | IPDMS Reference Number | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Date of receipt of application | STATUS |
|---------|------------------------|------------------------|---|---|-----------|---|--------------------------------|--------------------------------------|
| 33 | RPON2023050214 | 123050028 | Combi pack of Clarithromycin Tablets IP, Esomeprazole Tablets IP & moxycillin Tablets USP | Each Strip contains: A. Clarithromycin Tablets IP 2 Tablets Each film coated tablet contains: Clarithromycin IP 500mg B. Esomeprazole Tablets IP 2 Tablets Each Enteric coated tablet contains: Esomeprazole Magnesium Trihydrate IP eq. to Esomeprazole 40mg C. Amoxicillin Tablets USP 2 Tablets Each Film coated tablet contains: Amoxicillin Trihydrate IP eq. to Amoxicillin 1000mg | Tablets | M/s Malik Lifesciences Pvt. Ltd. / M/s Cipla Limited | 20-05-2023 | To be placed before Expert Committee |
| 34 | RPON2023050215 | 123050029 | Rabeprazole Sodium and Ondansetron Tablets | Each Film coated tablet contains: Rabeprazole Sodium IP 20mg (As Enteric Coated Form) Ondansetron Hydrochloride IP eq. to Ondansetron 4mg | Tablets | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Cipla Ltd. | 20-05-2023 | To be placed 115th Authority Meeting |
| 35 | RPON2023050216 | | Aceclofenac + Paracetamol + Serratiopeptidase Tablet | Each film coated tablet contains: Aceclofenac IP 100mg, Paracetamol IP 325mg Serratiopeptidase IP 15mg (As enteric coated granules eq. to 30000 enzyme activity unity of serratiopeptidase) | Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. /M/s Abbott Healthcare Pvt. Ltd. | 23-05-2023 | To be placed 115th Authority Meeting |
| 36 | RPON2023050217 | | Teneligliptin, Pioglitazone and Metformin Hydrochloride (as Sustained Release) Tablets | Each Film coated bilayered tablet contains: Teneligliptin Hydrobromide Hydrate IP eq. to Teneligliptin 20mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15mg Metformin Hydrochloride IP 500mg (as Sustained Release) | Tablet | M/s Synkem Pharmaceuticals Limited / M/s Micro Labs Limited | 23-05-2023 | To be placed before Expert Committee |
| 37 | RPON2023050218 | | Teneligliptin, Pioglitazone and Metformin Hydrochloride (as Sustained Release) Tablets | Each Film coated bilayered tablet contains: Teneligliptin Hydrobromide Hydrate IP eq. to Teneligliptin 20mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15mg Metformin Hydrochloride IP 1000mg (as Sustained Release) | Tablet | M/s Synkem Pharmaceuticals Limited / M/s Micro Labs Limited | 23-05-2023 | To be placed before Expert Committee |
| 38 | RPON2023050219 | | Paracetamol, Phenylephrine Hydrochloride and Chlorpheniramine Maleate Tablet | Each 5ml contains: Paracetamol IP 250mg Phenylephrine Hydrochloride 5mg Chlorpheniramine Maleate 2mg | Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Micro Labs Limited | 23-05-2023 | To be placed 115th Authority Meeting |
| 39 | RPON2023050220 | 123050019 | Sodium Chloride water for Injection & Ringers and Ringers Lacted 250ml Pack | Each 100ml contains: Lactic Acid IP 0.24ml (eq. to Sodium Lactate 0.32gm) Sodium Chloride IP 0.60gm Potassium Chloride IP 0.04gm Calcium Chloride IP 0.027gm Water for Injection | Injection | M/s Puniska Healthcare Pvt. Ltd. | 23-05-2023 | Clarification sought From DCGI |
| 40 | RPON2023050224 | | Azelnidipine and Temisartan Tablet | Each film coated tablet contains: Azelnidipine IP 16mg Temisartan IP 40mg. | Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Ipcal Laboratories Limited | 25-05-2023 | To be placed 115th Authority Meeting |

| Sl. No. | Acknowledgement Number | IPDMS Reference Number | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Date of receipt of application | STATUS |
|---------|------------------------|------------------------|---|---|------------|---|--------------------------------|--------------------------------------|
| 41 | RPON2023050225 | 123050032 | Paracetamol Paediatric Oral Suspension | Each ml contains: Paracetamol IP 100mg | Suspension | M/s Aristo Pharmaceuticals Pvt. Ltd. | 25-05-2023 | Clarification sought from DCGI |
| 42 | RPON2023050226 | | Glimepiride, Voglibose & Metformin Hydrochloride 1000mg (as Extended release form) tablet | Each uncoated Bilayered tablet contains: Glimepiride IP 1mg Voglibose IP 0.2mg Metformin Hydrochloride IP 1000mg (As Extended Release) | Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Alkem Laboratories Limited | 30-05-2023 | To be placed 115th Authority Meeting |
| 43 | RPON2023050227 | | Glimepiride, Voglibose & Metformin Hydrochloride 1000mg (as Extended release form) tablet | Each uncoated Bilayered tablet contains: Glimepiride IP 2mg Voglibose IP 0.2mg Metformin Hydrochloride IP 1000mg (As Extended Release) | Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Alkem Laboratories Limited | 30-05-2023 | To be placed 115th Authority Meeting |
| 44 | RPON2023060230 | | Glimepiride & Lobeglitazone Sulfate tablet | Each uncoated Bilayer tablet contains: Lobeglitazone Sulfate 0.5mg Glimepiride IP 1mg | Tablet | M/s Glenmark Pharmaceuticals Limited | 01-06-2023 | To be placed before Expert Committee |
| 45 | RPON2023060232 | | Vitamin D3 Oral Solution | Each 5ml contains: Cholecalciferol IP 60000IU (In Nano Droplet form) | Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Eris Lifesciences Limited | 01-06-2023 | To be placed 115th Authority Meeting |
| 46 | RPON2023060233 | | Cefixime Oral Suspension IP 30ml Pack | Each 5ml of reconstituted suspension contains: Cefixime IP (As Trihydrate) eq. to Anhydrous Cefixime 200mg | Tablet | M/s Alkem Healthscience (A unit of Alkem Laboratories Ltd.) / M/s Alkem Laboratories Ltd. | 01-06-2023 | To be placed 115th Authority Meeting |
| 47 | RPON2023060234 | | Cefixime Oral Suspension IP 60ml Pack | Each 5ml of reconstituted suspension contains: Cefixime IP (As Trihydrate) eq. to Anhydrous Cefixime 200mg | Tablet | M/s Alkem Healthscience (A unit of Alkem Laboratories Ltd.) / M/s Alkem Laboratories Ltd. | 01-06-2023 | To be placed 115th Authority Meeting |
| 48 | RPON2023060235 | 123050036 | Insulin Glargine 100IU /ml and Lixisenatide 50mcg/ml | Fixed Ratio combination of Insulin Glargine 100IU /ml Lixisenatide 50mcg/ml | Tablet | M/s Sanofi Healthcare India Pvt. Ltd. / M/s Sanofi India Limited | 02-06-2023 | To be placed before Expert Committee |
| 49 | RPON2023060236 | 123050037 | Insulin Glargine 100IU /ml and Lixisenatide 33mcg/m | Fixed Ratio combination of Insulin Glargine 100IU /ml Lixisenatide 33mcg/ml | Tablet | M/s Sanofi Healthcare India Pvt. Ltd. / M/s Sanofi India Limited | 02-06-2023 | To be placed before Expert Committee |
| 50 | RPON2023060242 | 123060001 | Amoxicillin + Potassium Clavulanate Oral Suspension | Each combi pack contains: (A) 1 Bottle of Amoxicillin and Potassium Clavulanate Oral Suspension IP Each 5ml of Constituted suspension contains: Amoxicillin Trihydrate IP eq. to Amoxicillin 400mg Potassium Clavulanate Diluted eq. to Clavulanic Acid 57mg (B) 1 Vial of Sterile water for Injections IP Each Vial Contains: Sterile water for Injections IP | Suspension | M/s Malik Life Sciences Pvt. Ltd. / M/s Blue Cross Laboratories Pvt. Ltd. | 05-06-2023 | Under Examination |
| 51 | RPON2023060243 | | Clobazam Oral Suspension | Each ml of the suspension contains: Clobazam IP 2.5mg | Suspension | M/s Windlas Biotech Limited / M/s Sanofi India Limited | 31-05-2023 | To be placed 115th Authority Meeting |
| 52 | RPON2023060244 | | Cefuroxime Axetil Tablets | Each film coated tablet contains: Cefuroxime Axetil eq. to Cefuroxime 250mg | Tablet | M/s Hetero Labs Limited / M/s Sun Pharmaceuticals Industries Limited | 06-06-2023 | To be placed 115th Authority Meeting |
| 53 | RPON2023060245 | | Cefuroxime Axetil & Potassium Clavulanate Tablets | Each film coated tablet contains: Cefuroxime Axetil IP eq. to Cefuroxime 500mg Potassium Clavulanate Diluted IP Eq. to Clavulanic Acid 125mg | Tablet | M/s Hetero Labs Limited / M/s Sun Pharmaceuticals Industries Limited | 06-06-2023 | Under Examination |

| Sl. No. | Acknowledgement Number | IPDMS Reference Number | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Date of receipt of application | STATUS |
|---------|------------------------|------------------------|---|--|-----------|---|--------------------------------|--------------------------------------|
| 54 | RPON2023060246 | | Oral Rehydration Salts with Zinc | Each sachet contains: Zinc Sulfate Monohydrate IP 0.011g Sodium Citrate IP 0.58g Potassium Chloride IP 0.30g Sodium Chloride IP 0.52g Dextrose Anhydrous IP 2.70g | Sachet | M/s Acme Diet Care Pvt. Ltd. / M/s Alkem Laboratories Limited | 07-06-2023 | To be placed 115th Authority Meeting |
| 55 | RPON2023060247 | | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 500mg | Tablet | M/s Morepen Laboratories Limited | 07-06-2023 | Clarification sought from Company |
| 56 | RPON2023060248 | | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 850mg | Tablet | M/s Morepen Laboratories Limited | 07-06-2023 | Clarification sought from Company |
| 57 | RPON2023060249 | | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 1000mg | Tablet | M/s Morepen Laboratories Limited | 07-06-2023 | Clarification sought from Company |
| 58 | RPON2023060250 | | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 500mg | Tablet | M/s Exemed Pharmaceuticals / M/s Corona Remedies Pvt. Ltd. | 07-06-2023 | To be placed 115th Authority Meeting |
| 59 | RPON2023060251 | | Budesonide and Formoterol Fumarate mistpules | Each 2 ml contains: Budesonide IP 1mg Formoterol Fumarate 20mcg | Mistpules | M/s Axa Parenterals Ltd./ M/s J.B. Chemicals & Pharmaceuticals Ltd. | 09-06-2023 | Working sheet uploaded |
| 60 | RPON2023050252 | | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 500mg | Tablet | M/s Synkem Lifesciences Pvt. Ltd. / M/s Mankind Pharma Ltd. | 26-05-2023 | To be placed 115th Authority Meeting |
| 61 | RPON2023050253 | | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 1000mg | Tablet | M/s Synkem Lifesciences Pvt. Ltd. / M/s Mankind Pharma Ltd. | 26-05-2023 | To be placed 115th Authority Meeting |
| 62 | RPON2023060254 | | Levosambutamol and Ipratropium Bromide respule solution | Each 2.5ml contains: Levosambutamol Sulphate IP eq. to Levosambutamol 1.25mg Ipratropium Bromide eq. to Ipratropium (anhydrous) 500mcg | Solution | M/s AXA Parenterals Ltd. / M/s Mankind Pharma Ltd. | 09-06-2023 | Under Examination |
| 63 | RPON2023060255 | 123060002 | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 1000mg | Tablet | M/s Synkem Pharmaceuticals Ltd. / M/s Cipla Ltd. | 09-06-2023 | To be placed 115th Authority Meeting |
| 64 | RPON2023060256 | 123060003 | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 500mg | Tablet | M/s Synkem Pharmaceuticals Ltd. / M/s Cipla Ltd. | 09-06-2023 | To be placed 115th Authority Meeting |
| 65 | RPON2023060257 | | Atorvastatin, Clopidogrel and Aspirin Capsules | Each hard gelation capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 40mg (As two film coated tablet) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg, Aspirin IP 75mg (As Gastro-resistant tablet) | Capsule | M/s Safetab Life Sciences / M/s Lupin Limited | 14-06-2023 | Under Examination |
| 66 | RPON2023060258 | | Dapagliflozin, Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each uncoated bilayer tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5mg Vildagliptin (As Sustained release) IP 100mg Metformin Hydrochloride (as Sustained Release) IP 500mg | Tablet | M/s Exemed Pharmaceuticals / M/s Alkem Laboratories Limited | 20-06-2023 | To be placed before Expert Committee |

| Sl. No. | Acknowledgement Number | IPDMS Reference Number | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Date of receipt of application | STATUS |
|---------|------------------------|------------------------|---|--|-----------------|---|--------------------------------|--------------------------------------|
| 67 | RPON2023060260 | 123060005 | Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each uncoated bilayered tablet contains: Vildagliptin (As Sustained release) IP 100mg Metformin Hydrochloride (as Sustained Release) IP 1000mg | Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Macleods Pharmaceuticals Ltd. | 22-06-2023 | To be placed 115th Authority Meeting |
| 68 | RPON2023060261 | 123060006 | Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each uncoated bilayered tablet contains: Vildagliptin (As Sustained release) IP 100mg Metformin Hydrochloride (as Sustained Release) IP 500mg | Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Macleods Pharmaceuticals Ltd. | 22-06-2023 | To be placed 115th Authority Meeting |
| 69 | RPON2023060262 | 123060007 | Dapagliflozin, Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each uncoated bilayer tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin (As Sustained release) IP 100mg Metformin Hydrochloride (as Sustained Release) IP 1000mg | Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Macleods Pharmaceuticals Ltd. | 22-06-2023 | To be placed 115th Authority Meeting |
| 70 | RPON2023060265 | 123060010 | Amoxicillin and Potassium Clavulanate Oral Suspension | Each 5ml of reconstituted suspension contains: Amoxicillin Trihydrate IP eq. to Amoxicillin 600mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 42.9mg | Oral Suspension | M/s MALIK LIFESCIENCES PVT LTD, / M/s Macleods Pharmaceuticals Ltd. | 22-06-2023 | To be placed 115th Authority Meeting |
| 71 | RPON2023060267 | 123060012 | Rosuvastatin & Clopidogrel Capsules | Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (as Pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets) | Capsule | M/s Synokem Pharmaceuticals Ltd / M/s Torrent Pharmaceuticals Limited | 23-06-2023 | Under Examination |
| 72 | RPON2023060268 | | Vildagliptin (SR) and Metformin Hydrochloride (SR) Tablets | Each film coated bilayered tablet contains: Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 500mg (as Sustained Release) | Tablet | M/s Synokem Pharmaceuticals Pvt. Ltd. / M/s Alkem Laboratories Pvt. Ltd. | 23-06-2023 | To be placed 115th Authority Meeting |
| 73 | RPON2023060269 | | Vildagliptin (SR) and Metformin Hydrochloride (SR) Tablets | Each film coated bilayered tablet contains: Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 1000mg (as Sustained Release) | Tablet | M/s Synokem Pharmaceuticals Pvt. Ltd. / M/s Alkem Laboratories Pvt. Ltd. | 23-06-2023 | To be placed 115th Authority Meeting |
| 74 | RPON2023060270 | 123060013 | Diclofenac Diethylamine, Methyl Salicylate and Menthol Gel | Composition: Diclofenac Diethylamine IP 2.32 % w/w eq. to Diclofenac Sodium IP 2.0 % w/w Methyl Salicylate IP 10 % w/w Menthol IP 5 % w/w | Gel | M/s Daiwik Pharmsphere Pvt. Ltd. / M/s Aristo Pharmaceuticals Pvt. Ltd. | 27-06-2023 | Working sheet uploaded |
| 75 | RPON2023060273 | | Clarithromycin for Oral Suspension USP | Each 5 ml of Reconstituted suspension contains: Clarithromycin IP 250mg | Oral Suspension | M/s Vapi Care Pharma Pvt. Ltd. / M/s Mankind Pharma Ltd. | 27-06-2023 | To be placed 115th Authority Meeting |
| 76 | RPON2023060274 | 123060015 | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 500mg | Tablet | M/s Sai Primus Life Biotech Private Limited / M/s Primus Remedies Pvt. Ltd. | 29-06-2023 | To be placed 115th Authority Meeting |
| 77 | RPON2023060275 | 123060016 | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 850mg | Tablet | M/s Sai Primus Life Biotech Private Limited / M/s Primus Remedies Pvt. Ltd. | 29-06-2023 | Working sheet uploaded |
| 78 | RPON2023060276 | 123060017 | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 1000mg | Tablet | M/s Sai Primus Life Biotech Private Limited / M/s Primus Remedies Pvt. Ltd. | 29-06-2023 | To be placed 115th Authority Meeting |

| Sl. No. | Acknowledgement Number | IPDMS Reference Number | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Date of receipt of application | STATUS |
|---------|------------------------|------------------------|---|---|-----------|---|--------------------------------|--------------------------------------|
| 79 | RPON2023060277 | | Vildagliptin (SR) and Metformin Hydrochloride (SR) Tablets | Each film coated bilayered tablet contains: Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 1000mg (as Sustained Release) | Tablet | M/s Synokem Pharmaceuticals Pvt. Ltd. / M/s Micro Labs Ltd. | 30-06-2023 | To be placed 115th Authority Meeting |
| 80 | RPON2023060278 | | Vildagliptin (SR) and Metformin Hydrochloride (SR) Tablets | Each film coated bilayered tablet contains: Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 500mg (as Sustained Release) | Tablet | M/s Synokem Pharmaceuticals Pvt. Ltd. / M/s Micro Labs Ltd. | 30-06-2023 | To be placed 115th Authority Meeting |
| 81 | RPON2023060279 | 123060018 | Moxifloxacin Eye Drops | Composition: Moxifloxacin hydrochloride IP eq. to Moxifloxacin 0.5%w/v Preservative : Benzalkonium Chloride Solution IP 0.02% w/v | Eye Drops | M/s East African (I) Overseas / M/s Torrent Pharmaceuticals Limited | 30-06-2023 | Under Examination |
| 82 | RPON2023070280 | | Clotrimazole & Lignocaine Hydrochloride Eye Drops | Composition: Clotrimazole IP 1.0% w/v Lignocaine Hydrochloride IP 2.0% w/v | Ear Drops | M/s Nuclotec Remedies Pvt. Ltd. / M/s Galpha Laboratories Ltd. | 03-07-2023 | Under Examination |
| 83 | RPON2023070281 | | Itraconazole Capsules 65mg (Supra- Bioavailable Formulation) | Each Hard gelatine capsule contains: (Supra-Bioavailable formulation) Itraconazole IP 65mg | Capsule | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Dr. Reddy's Laboratories Limited | 03-07-2023 | Under Examination |
| 84 | RPON2023070282 | | Itraconazole Capsules 65mg (Supra- Bioavailable Formulation) | Each Hard gelatine capsule contains: (Supra-Bioavailable formulation) Itraconazole IP 130mg | Capsule | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Dr. Reddy's Laboratories Limited | 03-07-2023 | Under Examination |
| 85 | RPON2023070283 | | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 1000mg | Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Glensmith Labs Pvt. Ltd. | 04-07-2023 | Working sheet uploaded |
| 86 | RPON2023070284 | | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 500mg | Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Glensmith Labs Pvt. Ltd. | 04-07-2023 | Working sheet uploaded |
| 87 | RPON2023070285 | | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 500mg | Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. | 04-07-2023 | Working sheet uploaded |
| 88 | RPON2023070286 | | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 1000mg | Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. | 04-07-2023 | Working sheet uploaded |
| 89 | RPON2023070287 | | Diclofenac Potassium & Metaxalone Tablets | Each uncoated tablet contains: Diclofenac Potassium BP 50mg Metaxalone USP 400mg | Tablets | M/s Windlas Biotech Limited / M/s Intas Pharmaceuticals Ltd. | 05-07-2023 | Under Examination |
| 90 | RPON2023070288 | | Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet | Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 500mg (Sustained Release Form) | Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Eris Lifesciences Limited | 06-07-2023 | To be placed before Expert Committee |

| Sl. No. | Acknowledgement Number | IPDMS Reference Number | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Date of receipt of application | STATUS |
|---------|------------------------|------------------------|--|--|-----------------|--|--------------------------------|--------------------------------------|
| 91 | RPON2023070289 | | Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet | Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 1000mg (Sustained Release Form) | Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Eris Lifesciences Limited | 06-07-2023 | To be placed before Expert Committee |
| 92 | RPON2023070290 | | Sitagliptin and Metformin Hydrochloride (Extended Released) Tablet | Each film coated Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Metformin Hydrochloride IP 1000mg (Extended Release Form) | Tablet | M/s Synkem Pharmaceuticals Limited / M/s Mankind Pharma Limited | 06-07-2023 | Under Examination |
| 93 | RPON2023070291 | | Metoprolol Succinate Extended Release, Amlodipine 5mg & Telmisartan Tablet | Each film coated bilayered tablet contains: Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartrate 50mg (As Extended release) Amlodipine Besilate IP IP eq. to Amlodipine 5mg Telmisartan IP 40mg | Tablet | M/s Ajanta Pharma Limited | 07-07-2023 | To be placed before Expert Committee |
| 94 | RPON2023070292 | | Calcium, Vitamin D3, Magnesium & Zinc Tablets | Each uncoated tablet contains: Calcium Citrate USP 1000mg Vitamin D3 IP 200IU Magnesium Hydroxide IP eq. to elemental magnesium 100mg Zinc Sulphate Monohydrate IP eq. to elemental Zinc 4mg | Tablet | M/s Hanuchem Laboratories / M/s Mankind Pharma Ltd. | 07-07-2023 | Under Examination |
| 95 | RPON2023070293 | | Telmisartan and Metoprolol Succinate (ER) Tablet | Each film coated bilayered tablet contains: Telmisartan IP 40mg Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate 25mg (as extended release form) | Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s La Renon Healthcare Pvt. Ltd. | 08-07-2023 | Under Examination |
| 96 | RPON2023070294 | | Telmisartan and Metoprolol Succinate (ER) Tablet | Each film coated bilayered tablet contains: Telmisartan IP 40mg Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartrate 50mg (as extended release form) | Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s La Renon Healthcare Pvt. Ltd. | 08-07-2023 | Under Examination |
| 97 | RPON2023070295 | | Phenylephrine Hydrochloride and Chlorpheniramine Maleate Syrup | Each 5ml contains: Phenylephrine Hydrochloride IP 5.0mg Chlorpheniramine Maleate IP 2.0mg | Syrup | M/s Windlas Biotech Limited / M/s Biological E. Limited | 09-07-2023 | Under Examination |
| 98 | RPON2023070296 | | Paracetamol, Phenylephrine HCl, Chlorpheniramine maleate, Ammonium Chloride, Sodium Citrate & Menthol suspension | Each 5ml (teaspoonful) contains: Paracetamol IP 250mg Phenylephrine Hydrochloride IP 5mg Chlorpheniramine maleate IP 2mg Ammonium Chloride IP 120mg Sodium Citrate IP 60mg Menthol IP 1mg | Oral Suspension | M/s Windlas Biotech Limited / M/s Biological E. Limited | 09-07-2023 | Under Examination |
| 99 | RPON2023070297 | | Pantoprazole Dual Release Gastro Resistant Tablets | Each Dual Release Gastro Resistant Tablet Contains: Pantoprazole Sodium Eq. to Pantoprazole 80mg | Oral Suspension | M/s Pure & Cure Healthcare Pvt. Ltd. / M/s Mankind Pharma Ltd. | 10-07-2023 | Under Examination |
| 100 | RPON2023070298 | | Linagliptin + Metformin Hydrochloride Extended Release Tablet | Each film coated bilayer tablet contains: Linagliptin 5mg Metformin Hydrochloride (As extended release)IP 1000mg | Tablet | M/s Exemed Pharmaceuticals / M/s Intas Pharmaceuticals Ltd. | 11-07-2023 | To be placed before Expert Committee |

| Sl. No. | Acknowledgement Number | IPDMS Reference Number | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Date of receipt of application | STATUS |
|---------|------------------------|------------------------|---|--|--------|--|--------------------------------|--------------------------------------|
| 101 | RPON2023070299 | | Linagliptin + Metformin Hydrochloride Extended Release Tablet | Each film coated bilayer tablet contains: Linagliptin 2.5mg Metformin Hydrochloride (As extended release)IP 1000mg | Tablet | M/s Exemed Pharmaceuticals / M/s Intas Pharmaceuticals Ltd. | 11-07-2023 | Under Examination |
| 102 | RPON2023070300 | 123070002 | Metoprolol Succinate Extended Release and Amlodipine Tablet | Each film coated bilayered tablet contains: Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartrate 50mg (As Extended release) Amlodipine Besilate IP eq. to Amlodipine 5mg | Tablet | M/s Ajanta Pharma Limited | 07-07-2023 | Under Examination |
| 103 | RPON2023070301 | 123070004 | Dapagliflozin, Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each uncoated bilayer tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin (As Sustained release) IP 100mg Metformin Hydrochloride (as Sustained Release) IP 500mg | Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Primus Remedies Pvt. Ltd. | 11-07-2023 | To be placed before Expert Committee |
| 104 | RPON2023070302 | 123070005 | Dapagliflozin, Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each uncoated bilayer tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin (As Sustained release) IP 100mg Metformin Hydrochloride (as Sustained Release) IP 1000mg | Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Primus Remedies Pvt. Ltd. | 11-07-2023 | To be placed before Expert Committee |
| 105 | RPON2023070303 | | Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet | Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 1000mg (Sustained Release Form) | Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Intas Pharmaceuticals Ltd. | 12-07-2023 | To be placed before Expert Committee |
| 106 | RPON2023070304 | | Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet | Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 500mg (Sustained Release Form) | Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Intas Pharmaceuticals Ltd. | 12-07-2023 | To be placed before Expert Committee |
| 107 | RPON2023070305 | 123070010 | Dapagliflozin, Sitagliptin and Metformin Hydrochloride (as Extended Release) Tablets | Each uncoated bilayer tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Sitagliptin Phosphate IP eq. to Sitagliptin 100mg Metformin Hydrochloride (as Extended Release) IP 500mg | Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Macleods Pharmaceuticals Ltd. | 12-07-2023 | Under Examination |
| 108 | RPON2023070306 | 123070011 | Dapagliflozin, Sitagliptin and Metformin Hydrochloride (as Extended Release) Tablets | Each uncoated bilayer tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Sitagliptin Phosphate IP eq. to Sitagliptin 100mg Metformin Hydrochloride (as Extended Release) IP 1000mg | Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Macleods Pharmaceuticals Ltd. | 10-07-2023 | Under Examination |
| 109 | RPON2023070308 | 123070007 | Ceftriaxone & Sulbactam Injection | Each uncoated sustained release tablet contains: Nitrofurantoin IP 100mg | Tablet | M/s Nuclotec Remedies Pvt. Ltd. / M/s Obsurge Biotech Ltd. | 13-07-2023 | Under Examination |

| Sl. No. | Acknowledgement Number | IPDMS Reference Number | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Date of receipt of application | STATUS |
|---------|------------------------|------------------------|--|--|------------|---|--------------------------------|-------------------|
| 110 | RPON2023070311 | 123070012 | Paracetamol, Phenylephrine Hydrochloride, Caffeine & Diphenhydramine Hydrochloride Tablets | Each uncoated tablet contains: Paracetamol IP 500mg Phenylephrine Hydrochloride IP 5mg Diphenhydramine Hydrochloride IP 25mg Caffeine (Anhydrous) IP 30mg | Tablet | M/s Prosperity Drugs Pvt. Ltd. / M/s Torrent Pharmaceuticals Limited | 14-07-2023 | Under Examination |
| 111 | RPON2023070312 | 123070013 | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 500mg | Tablet | M/s Macleods Pharmaceuticals Ltd. | 14-07-2023 | Under Examination |
| 112 | RPON2023070313 | 123070014 | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 1000mg | Tablet | M/s Macleods Pharmaceuticals Ltd. | 14-07-2023 | Under Examination |
| 113 | RPON2023070314 | 123070015 | Telmisartan, Chlorthalidone & Cilnidipine tablets | Each film coated tablet contains: Telmisartan IP 40mg Chlorthalidone IP 6.25mg Cilnidipine IP 10mg | Tablet | M/s Macleods Pharmaceuticals Ltd. | 14-07-2023 | Under Examination |
| 114 | RPON2023070316 | | Brinzolamide, Brimonidine Tartrate & Timolol Ophthalmic suspension | Each ml contains: Brinzolamide IP 10mg Brimonidine Tartrate IP 2 mg Timolol Maleate eq. to Timolol IP 5 mg Benzalkonium Chloride Solution IP 0.2mg (As Preservative) Water for injection | Suspension | M/s Micro labs Limited | 19-07-2023 | Under Examination |
| 115 | RPON2023070317 | | Tenofovir Disoproxil Fumarate, Emtricitabine & Efavirenz IP Tablet | Each film coated tablet contains: Tenofovir Disoproxil Fumarate IP 300mg (Eq. to Tenofovir Disoproxil 245mg), Emtricitabine IP 200mg Efavirenz IP 600mg | Tablet | M/s Hetero Healthcare Ltd. | 19-07-2023 | Under Examination |
| 116 | RPON2023070318 | | Povidone Iodine Gargle | Composition: Povidone Iodine IP 0.5% w/v (available Iodine 0.05% w/v) | Solution | M/s Pontika Aerotech Limited / M/s Emcure Pharmaceuticals Limited | 19-07-2023 | Under Examination |
| 117 | RPON2023070319 | | Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet | Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 500mg (Sustained Release Form) | Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Intas Pharmaceuticals Ltd. | 25-07-2023 | Under Examination |
| 118 | RPON2023070320 | | Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet | Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 1000mg (Sustained Release Form) | Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Intas Pharmaceuticals Ltd. | 25-07-2023 | Under Examination |
| 119 | RPON2023070321 | | Dapagliflozin, Sitagliptin and Metformin Hydrochloride (ER) Tablets | Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5mg Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 50mg Metformin Hydrochloride IP 500mg (As Extended Release form) | Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Alkem Laboratories Limited | 21-07-2023 | Under Examination |

| Sl. No. | Acknowledgement Number | IPDMS Reference Number | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Date of receipt of application | STATUS |
|---------|------------------------|------------------------|---|--|-----------|---|--------------------------------|-------------------|
| 120 | RPON2023070322 | | Dapagliflozin, Sitagliptin and Metformin Hydrochloride (ER) Tablets | Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5mg Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg (As Extended Release form) | Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Alkem Laboratories Limited | 21-07-2023 | Under Examination |
| 121 | RPON2023070323 | 123070019 | Paracetamol and Dicyclomine Hydrochloride Tablets | Each uncoated tablet contains: Paracetamol IP 325mg Dicyclomine Hydrochloride IP 20mg | Tablet | M/s Prosperity Drugs Pvt. Ltd. / M/s Torrent Pharmaceuticals Limited | 21-07-2023 | Under Examination |
| 122 | RPON2023070324 | 123070020 | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP (as Extended release) 1000mg | Tablet | M/s Synkem Pharmaceuticals Ltd. / M/s Cipla Ltd. | 25-07-2023 | Under Examination |
| 123 | RPON2023070325 | 123070021 | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 5mg Metformin Hydrochloride IP (as Extended release) 1000mg | Tablet | M/s Synkem Pharmaceuticals Ltd. / M/s Cipla Ltd. | 25-07-2023 | Under Examination |
| 124 | RPON2023070326 | | Tenofovir Alafenamide, Emtricitabine & Bictegravir Tablet | Each film coated tablet contains: Tenofovir Alafenamide Hemifumarate 1H eq. to Tenofovir Alafenamide 25mg, Emtricitabine IP 200mg Bictegravir Sodium 1H eq. to Bictegravir 50mg | Tablet | M/s Hetero Labs Ltd. / M/s Hetero Healthcare Ltd. | 25-07-2023 | Under Examination |
| 125 | RPON2023070327 | | Linagliptin + Metformin Hydrochloride (ER) Tablet | Each film coated tablet contains: Linagliptin 5mg Metformin Hydrochloride (as Extended release) IP 1000mg | Tablet | M/s Exemed Pharmaceuticals Ltd. / M/s Micro Labs Ltd. | 26-07-2023 | Under Examination |
| 126 | RPON2023070328 | | Ibuprofen Solution for Infusion 400mg/100ml | Each 100ml contains: Ibuprofen IP 400mg water for injection | Injection | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Neon Laboratories Limited | 27-07-2023 | Under Examination |
| 127 | RPON2023070329 | 123070023 | Metoprolol Succinate Extended Release, Cilnidipine & Telmisartan Tablet | Each film coated bilayered tablet contains: Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate IP 25mg (As Extended release) Telmisartan IP 40mg, Cilnidipine IP 10mg | Tablet | M/s Unison Pharmaceuticals Pvt. Ltd. | 27-07-2023 | Under Examination |
| 128 | RPON2023070330 | 123070022 | Metoprolol Succinate Extended Release, Cilnidipine & Telmisartan Tablet | Each film coated bilayered tablet contains: Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartrate IP 50mg (As Extended release) Telmisartan IP 40mg, Cilnidipine IP 10mg | Tablet | M/s Unison Pharmaceuticals Pvt. Ltd. | 27-07-2023 | Under Examination |
| 129 | RPON2023070331 | 123070024 | Linagliptin + Metformin Hydrochloride (ER) Tablet | Each film coated bilayered tablet contains: Linagliptin 5mg Metformin Hydrochloride (as Extended release) IP 1000mg | Tablet | M/s Synkem Pharmaceuticals Ltd. / M/s Torrent Pharmaceuticals Ltd. | 28-07-2023 | Under Examination |